CardioVascular BioTherapeutics

Name

CardioVascular BioTherapeutics

Legal name

Venturis Therapeutics, Inc.

Website

https://cvbt.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)

akta.pro secondary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Protein therapeutics
• Clinical-stage biopharmaceutical
• Angiogenesis therapy
• Cardiovascular drug development
• Ischemic disease treatment

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical stage biopharmaceutical company developing protein drug candidates for cardiovascular diseases. Revenue will be generated through pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Venturis Therapeutics is a clinical-stage biopharmaceutical company developing protein drug candidates derived from the human Fibroblast Growth Factor (FGF) family to stimulate the growth of new blood vessels (therapeutic angiogenesis) when administered to ischemic organs and tissues. Lead clinical programs target diabetic wounds, severe ischemic heart disease, and peripheral artery disease, with additional pre-clinical programs in erectile dysfunction, infarct stroke, degenerative disk disease, and Parkinson's Disease.

Product overview

Venturis Therapeutics is a clinical stage biopharmaceutical company developing a unified portfolio of protein drug candidates based on human Fibroblast Growth Factor (FGF) family proteins. The company's lead therapeutic candidate is designed to stimulate angiogenesis (growth of new blood vessels) in ischemic organs and tissues. The product pipeline addresses both clinical-stage indications (diabetic wounds, severe coronary heart disease, peripheral artery disease) and pre-clinical programs (erectile dysfunction, infarct stroke, degenerative disk disease, and Parkinson's Disease). The company focuses on targeted delivery of next-generation molecules to improve quality of life for patients suffering from vascular dysfunction.

Differentiator

Problem solved

Functional benefit

Products and services

• Fibroblast Growth Factor (FGF) Protein Therapeutics Human protein drug candidates derived from the Fibroblast Growth Factor (FGF) family, designed to stimulate growth of new blood vessels (therapeutic angiogenesis) when administered to ischemic organs and tissues. Targets diabetic wounds, severe ischemic heart disease, and peripheral artery disease in clinical stage.
• FGF Therapeutic for Diabetic Wounds Clinical-stage FGF-based therapeutic candidate intended to address poor wound healing caused by impaired blood flow and vascular dysfunction in diabetic patients.
• FGF Therapeutic for Severe Ischemic Heart Disease Clinical-stage FGF-based therapeutic candidate designed to regenerate blood vessels and restore blood flow in patients with severe coronary heart disease and myocardial ischemia.
• FGF Therapeutic for Peripheral Artery Disease Clinical-stage FGF-based therapeutic candidate intended to restore blood flow to extremities in patients with peripheral artery disease, addressing pain, tissue damage, and risk of limb loss.

Quantifiable outcome

• Stimulates new blood vessel growth in ischemic organs and tissues

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• David G. Armstrong DPM MD PhDcoreOthers · 6 June 2023Affiliation announced June 6, 2023 with David G. Armstrong DPM MD PhD, described as the most noted authority on the diabetic foot. Provides expertise in diabetic foot care and wound healing.
• Prevail InfoWorks, Inc. and Prevail Partners, LLCcoreStrategic or Co-development Partner · 9 September 2021Strategic alliance announced September 9, 2021 with Prevail InfoWorks, Inc. and Prevail Partners, LLC for collaborative partnership in advancing therapeutic development programs.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• AnGes: Japanese clinical-stage biopharmaceutical developer of HGF gene therapy for peripheral arterial disease and other angiogenic indications. Closely comparable given its therapeutic angiogenesis platform targeting PAD, the same indication pursued by Venturis.
• BioCardia: Clinical-stage developer of cell and gene therapies for cardiovascular disease, including heart failure and ischemic conditions. Directly comparable as a small-cap clinical-stage biotech using biological mechanisms to treat ischemic cardiovascular indications.
• Armaron Bio: Australian clinical-stage biopharmaceutical company developing cardiovascular therapies targeting endothelial dysfunction and vascular disease. Comparable as a small clinical-stage biotech with a vascular regeneration mechanism of action.
• Tenax Therapeutics: Small-cap clinical-stage biopharmaceutical company developing cardiovascular therapies for heart failure and pulmonary hypertension. Comparable as a similarly-sized US-based clinical-stage cardiovascular biotech.
• Capricor Therapeutics: Clinical-stage biopharmaceutical company developing cell-based and biologic therapies for Duchenne muscular dystrophy and cardiovascular diseases. Comparable as a small clinical-stage biologics developer targeting cardiovascular indications with a novel therapeutic modality.

Others

• Cardium Therapeutics (now part of Taxus Cardium / dormant): Historical clinical-stage biopharmaceutical company that developed biologic cardiovascular therapies, including angiogenic gene therapy for myocardial ischemia. Comparable as a legacy angiogenesis-focused cardiovascular biotech whose commercial trajectory illustrates the execution challenges of the space.

Broad incumbents

• MiMedx Group: Public regenerative medicine company developing placental tissue allografts for wound care (including diabetic foot ulcers) and surgical applications. Comparable given its commercial focus on diabetic wound healing and vascular-driven tissue repair, even though its modality (tissue allograft) differs from FGF protein therapeutics.
• Diffusion Pharmaceuticals: Clinical-stage biopharmaceutical company developing small-molecule therapeutics for cardiovascular and oncology indications. Comparable as a similarly-sized US clinical-stage biotech working on cardiovascular indications, though with a different mechanism.
• Caladrius Biosciences: Clinical-stage biopharmaceutical company developing cell therapies for cardiovascular disease and immuno-oncology. Comparable as a small clinical-stage company with cardiovascular regenerative medicine assets and a similarly constrained capitalization profile.

Emerging players

• Helixmith (formerly Vical): Biopharmaceutical company developing DNA-based therapeutics, historically including angiogenesis programs for cardiovascular indications. Comparable given its historical focus on plasmid-based angiogenic growth factors (similar FGF/VEGF biology), though it has shifted focus to gene therapy for neurologic indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CardioVascular BioTherapeutics